Drug Trial Radar · NCT04925661
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 4, 2021
Primary completion
Aug 29, 2023
Study completion Aug 29, 2023
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Nicoya Therapeutics (Shanghai) Co., Ltd.
- First posted
- Jun 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability , pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Patients With Non-dialysis Renal Anemia.
Conditions
- Chronic Kidney Diseases
- Renal Anemia
Interventions
HEC53856Drug
Either dose of HEC53856 will be administered after fasting .
RoxadustatDrug
Roxadustat will be administered after fasting .
PlaceboDrug
Either dose of placebo will be administered after fasting .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Through study completion, an average of 12 weeks.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
The sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Zhejiang Provincal People's Hospital
Hangzhou, China
The People's Hospital of Guangxi Zhuang Autonmous Region
Nanning, China
Huashan Hospital
Shanghai, China
Ruijin Hospital
Shanghai, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.